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In late December 2009, we revised and significantly altered our strategies for public advertisement for enrollment. This new strategy yielded the anticipated outcomes. Between December 28 th 2009 and January 28 th 2010, we received at total of 235 phone calls from military veterans interested in our research studies. Of these, 48 received information for the ongoing clinical trial and were potential participant in the present neuroimaging study. Those who were not eligible included non-OEFjOIF veterans, veterans using exclusionary medications, those who reported having sleep apnea, or declined participation in the study. Four eligible partiCipants with PTSD have been consented and are currently completing the screening and baseline phase of the parent randomized controlled trial. These could be eligible for this neuroimaging study should they be randomized to the medication arms of the randomized controlled trial. We continue to try to recontact four additional individuals who initially appeared eligible and interested, but who have not yet been scheduled for consent and intake visit.
In summary, our latest recruitment strategies have been fruitful and show significant progress in enrollment for the current study.
• Randomize eligible participants with PTSD into the ongoing treatment trial (Months 6-42; NCTRC). For participants randomized to the medication arms (prazosin or placebo), complete screening magnetic resonance (MR) scans. (Months 6-42; UPMC MR Center)
PROGRESS: This sub-task is ongoing. As indicated above, six veterans with PTSD are currently in the screening and baseline phase of the parent randomized controlled trial, to which this current neuroimaging study is attached for the rest of the parent study. Should these participants be randomized to the medication arms of the parent randomized controlled trial, they will be enrolled in the present study.
It is important to note that the parent randomized controlled trial is scheduled for termination in March 2010, as initially anticipated and planned. For the reminder of this current project, the treatment protocol will continue as currently conducted, except that participants can now only be randomized to one of the 2 medication arms (prazosin or placebo), rather than the current 1: 1 randomization to medication or behavioral treatment arms. This will greatly facilitate recruitment and flow of subjects through the present neuroimaging protocol, because 1) only OEFjOIF veterans will be enrolled in this continuing study; and 2) the randomization will be limited to the medication arms (prazosin or placebo) that are directly involved in the present study, rather than the current 1: 1 randomization to medication or behavioral treatment. As such, the management of recruitment efforts and subject flow through screening and baseline research procedures will be exclusively focused on OEFjOIF veterans to be enrolled in this study. We are thus confident that the number of enrolled participants will be significant increased over the next funding periods, and that we will meet the targeted enrollment goals over the course of the award.
Task 2: To compare the neurobiology of PTSD during REM sleep and NREM sleep relative to wakefulness in returnees with and without PTSD (Months

6-48; NCTRC and UPMC PET Center).
• Conduct pre-treatment (baseline) clinical, polysomnographic, and PET scan studies in participants with PTSD who elect to take part in this study (Months 6-42; NCTRC, UPMC PET Center).
PROGRESS:
• Recruit age-and sex-matched returnees without PTSD (Months 9-45; NCTRC)
PROGRESS: This sub-task is ongoing. Two male participants without PTSD have completed the protocol to date. Our recent successfui recruitment efforts indicate that we can also reach OEFjOIF veterans without PTSD. We do not anticipate difficulties in recruitment and completing the protocol with this group in the coming funding period.
• Process MR and PET scans (Months 6-46; NCTRC and PET)
PROGRESS: This sub-task is ongoing. Imaging data review, alignment, processing, and archiving for analysis is conducted on a timely manner.
• Conduct preliminary and confirmatory statistical analyses with Statistical Parametric Mapping, version 2 (SPM-2) to evaluate Group (PTSD vs. Non-PTSD) X State (Wakefulness vs. NREM; Wakefulness vs. REM sleep) differences in absolute and relative regional cerebral metabolic rate of glucose (rCMRglc; Months 36-48; NCTRC).
PROGRESS: This sub-task is not applicable for this review period.
• Conduct preliminary and confirmatory statistical analyses with SPM-2 to evaluate the neurobiological correlates of nightmares and insomnia during REM and NREM sleep in PTSD patients (Months 36-48).
Task 3: To identify the neurobiological changes associated with sleep treatment response during REM sleep and NREM sleep relative to wa kefu Iness.
• Administer and monitor treatment protocols in participants with PTSD (Months 6-45; NCTRC)
PROGRESS: As indicated above, sub-tasks related to recruitment, randomization, and treatment have been hampered, and remain ongoing. Treatment protocols with prazosin and placebo are maintained as originally proposed. We do not anticipate problems in administering and monitoring treatments in participants with PTSD who will initiate treatment in the coming funding period.
• Conduct and complete 8=weekly treatment sessions and weekly ratings of clinical changes, treatment adherence, and side effects (Months 6-45; NCTRC)
• Monitor safety and adverse events (Months 6-45; NCTRC)
PROGRESS: As indicated above, sub-tasks related to recruitment, randomization, and treatment have been hampered, and remain ongoing. Protocols for monitoring and reporting safety and adverse events have been established, and are reviewed monthly with the study physician and team.
• Complete post-treatment assessments by using polysomnographic studies and PET scan studies, clinician-administered and self-report scales of sleep quality and disturbances, PTSD symptom severity, depression, anxiety, and health-related quality of life in participants with PTSD who cOlTlplete the treatment protocoi(Montns 9-45; NCTRC)
PROGRESS: As indicated above, sub-tasks related to recruitment, randomization, and treatment have been hampered, and remain ongoing. Protocols to complete post-treatment assessments and procedures are in place.
• Identify treatment responders and non-responders. sleep treatment response is defined as a post-treatment sleep latency < 30 PROGRESS: This sub-task is not applicable for this review period.
III. KEY RESEARCH ACCOMPLISHMENTS
• Development and implementation of successful recruitment strategies using public media.
;; Initiation of complementary archival data analysis for anticipated comparisons of the neurobiological correlates that will subsequently be used to distinguish 1) combat-exposed veterans without PTSD to healthy civilians sleepers across the sleep-wake cycle; 2) veterans with PTSD to civilians with major depression or primary insomnia (two highly comorbid conditions in PTSD) across sleep and wake states. relates to the present study in identifying the potential neurobiological sources of beta activity (a marker of arousal) during REM sleep in healthy and clinical samples, for future comparisons with data to be collected in the present study. The research abstract summarizing these findings has been submitted for presentation at the SLEEP 2010 meeting (provided with this submission).
2. Mr. Daniel Cohen is a 1 st year medical student at the University of Pittsburgh who completed a summer research project under Dr. Germain's supervision between May and August 2009. Mr. Cohen's project aims at comparing beta activity during REM sleep in returning veterans with and without PTSD using quantitative EEG analysis. Data processing is almost complete, and analysis will be undertaken in the coming weeks. It is anticipated that a research abstract summarizing these findings will be submitted for presentation at the SLEEP 2010 meeting. As heightened arousal is a core construct of the models to be tested in the present study, evaluating whether group differences in quantitative EEG measures of central arousal may provide some preliminary findings regarding overall hyperarousal during REM sleep in veterans with PTSD compared to veterans without PTSD. The research abstract summarizing these findings has been submitted for presentation at the SLEEP 2010 meeting (provided with this submission).
Mr. Roger Huijon is a 1
st year medical student at the University of Pittsburgh who completed a summer research project under Dr. Germain's supervision between May and August 2009. His project aimed at comparing the neurobiological correlates of REM sleep relatively to wakefulness in patients with depression and insomnia. Preliminary findings indicated a complex functional neuroanatomical profile, and supplemental analyses are underway. This project will provide unique and novel data regarding neurobiological differences and similarities in rCMRgic during REM sleep relative to wakefulness in two clinical samples: patients with major depression and patients with insomnia. As PTSD is characterized by both high levels of comorbid depression and insomnia, this summer project will provide some additional insight into the specific and unique neurobiological correlates of REM sleep in veterans with and without PTSD.
4. Mrs. Tanisha Hill-Jarrett is a Psychology Honors Student at University of Pittsburgh who started working with Dr. Germain in August 2009 on an imaging project aimed at comparing the neurobiological correlates of NREM sleep relative to wakefulness in adults with depression or insomnia. She is currently working on data analysis and interpretation. Her honors dissertation defense is scheduied for AprilS, 2010. This project directly relates to the present study in identifying the potential neurobiological differences that characterize major depression and insomnia, two frequently comorbid conditions in military veterans with PTSD. Understand how depression and insomnia differ (or are similar) from wakefulness to NREM sleep in adult civilian samples will provide a comparative background to assess how veterans with and without PTSD differ from these two samples (or are Similar to) across physiological states.
V. CONCLUSION
Recruitment and research activities and procedures remain ongoing. Recruitment has I accrued at a slower pace than initially anticipated, but our recent successful recruitment strategies have proven fruitful, and we are confident that we can meet I our targeted recruitment goals. We continue to develop collaborative relationships with local veterans' resources at the University as well as those located at other colleges.
While preliminary results are not expected for another 12 to 15 months, we have initiated complementary work using archival imaging data collected in adults with major depression or insomnia, and healthy, civilian control subjects. These analyses and report writing are ongoing, and findings will provide a comparative background for the antiCipated findings in OEFjOIF veterans with and without PTSD. This will constitute a unique set of comparisons to identify and determine the neurobiological underpinnings that differ among clinical and health samples.
Anticipated imaging data before and after treatment with prazosin or placebo will also provide novel insights in the possible mechanisms underlying sleep treatment response to inform new detection, prevention, and treatment strategies that address both nighttime and daytime symptoms of PTSD and other stress-related disorders in I military personnel.
VI. REFERENCES
None applicable.
VII. APPENDICES
• Abstracts submitted for the 2010 SLEEP Meeting
• Relevant published papers
VIII. SUPPORTING DATA
None to provide at this time.
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List of personnel receiving pay from the research effort: NAME (role) Introduction: Primary (PI) insomnia is characterized by increased arousal and poor sleep. However, the neurobiological correlates of PI during REM sleep have been scarcely studied. We explored the relationship between whole-night absolute beta power during REM sleep and relative regional cerebral metabolic rate of glucose (rCMRglc) in adults with PI.
Methods: 10 PI subjects (M age= 37.86 ± 9.38 years) were included in this analysis. All were medication-free and completed 3 nights of polysomnographic recordings, and 
Abstract:
Titie: Quantitative EEG analysis in REM sleep in OEF/OIF combat veterans with and without PTSD.
Authors: Daniel Cohen, Jennie Alman, David Cashmere, Jean Miewald, Anne Germain I ntrod uction REM sleep disturbances have been associated with Posttraumatic Stress Disorder (PTSD), but PSG studies have yielded inconsistent findings. In this study, we used quantitative EEG (qEEG) to compare beta activity (16-32Hz) as a measure of central arousal during REM sleep in combatexposed veterans with and without PTSD. We hypothesized that PTSD would be associated with greater beta activity.
Methods:
Participants were combat veterans of Operations Enduring/Iraqi Freedom (OEF/OIF) drawn from an ongoing clinical trial. Assessments included 2 PSG nights, and questionnaires on sleep quality and psychiatric symptoms. Participants using psychotropic medications were excluded from this analysis. The second PSG night was used for qEEG analysis. Artifacts were rejected in 4-second epochs using an automated algorithm for EMG-twitches, and manually to remove eye-movement and pulse artifacts. Artifact-free REM epochs were subjected to spectral analysis using a fast Fourier transform model. T-tests were used to compare groups. Spearman correlations were performed between beta activity and clinical variables.
Results:
No group differences were observed on PSG measures. The number of 4-second REM epochs rejected for qEEG analysis did not differ between groups. The PTSD group showed lower beta activity in REM sleep than the non-PTSD-group (mean (SD): 0.060 (0.02) vs. 0.096 (0.03), p=O.013). No differences were observed in other qEEG activity bands. In the combined sample, REM beta activity was negatively correlated to PTSD symptom severity (rho=-O.S2, p=O.04), PTSD avoidance symptoms (rho=-0.S7, p=0.02), but not to hyperarousal symptoms (rho=-0.09, p=0.7S).
Discussion:
Contrary to our hypothesis, beta activity was lower during REM sleep in combat veterans with PTSD compared to those without PTSD, and was not related to hyperarousal symptom severity. This small study raises the possibility of a complex, non-linear link between central hyperarousal, REM sleep, and PTSD symptom severity. 
Dreams and Nightmares in PTSD
Dream Recall and Nightmare-Related PTSD
Studies on dream recall frequency following trauma exposure have yielded inco~siste~t results. ·Increases in dream recall frequency following a traumatic event ha ve been reported and the hypothesis put forth is that dream recall is facilitated hy the intensity, affective charge, and references to the victims' trauma depicted in their dreams. Conversely, significant decreases in dream recall have also been documented. These data, however, are largely based on retrospective assessments conducted many months or even several years fol~ lowing trauma exposure. It is possible that dream recall increases immediately following an individual's exposure to tra uma and subsequently diminishes over time. One comparison of high~functioning Holocaust survivors, average~functi()ning Holocaust survivors, and controls found that the high~functioning survivors reported fewer dreams from REM sleep (33.7%), c()m~ pared to the average~functi()ning survivors (50.5%) 
Repetition of Trauma in Dreams
The recall of dreams that replicate the traumatic event experienced by trauma victims has been described in manv populations, including war veterans, adults and children exposed to war, witnesses of violence and abuse, burn victims, and Individuals exposed to natural disasters. A classification syste1l1 for trauma-I-elated dreams has been put forth. Posttraumatic dreams refer to the replication of the traumatic event during sleep or the introduction of the cncJpsubted memorv of the trauma during sleep. Modified dreams present distorted themes, elcments, or emotions from the trauma. Finallv, disguised dreams rcpresent the traumatic event symbolically or 1l1etaphorlcall\,. These categories form ~l continuum of replicatloll (according to the extent to which the traumatic evcllt is represented in the dream) and of I-epetition (i.e., the dream's recurrence). Empirical studies support this classification svstem. For example, in one study of Vietnam \var veterans, ,j()4 of 316 veterans reported com bat-related nightmares. An examinatiol\ of their dream narratives revealed that over half of the veterans reported realistic combat dreams, 21 'Y,o reported plausible war sequences that they nevertheless had not experienced, and 26% reported dreams that alluded to the war, but also included fantastical and elements. In addition, a laboratory study of war veterans found that only 21 % of dreams exactly replicated the traumatic event, while the majority contained distortions related to the traumatic event. Similarly, one study of patients hospitalized following an accident or assault found that 46% of reported dreams replicated the traumatic event, 33 % were dissimilar to the traumatic event while containing high levels of distress, and 19°/c) showed little similarity to the trauma or distress.
Taken together, the results reveal changes in dream content with the passage of time and with improvement in the posttrauma reaction. Dreams recalled during the initial posttwuma phase tend to include some type of repetition of the trauma while subsequent phases are characterized by more symbolic representations of the trauma and greater integration of the individual's everyday life in recalled dream content.
Trauma and Dream Content
Several studies have reported salient alterations in the content of trauma victims' dreams. Some data suggest that when compared to the dream reports from controls, dreams recalled by trauma victims tend to be more ordinary Jnd realistic and less salient, bizarre, and imaginative. The 'ordinary' quality of trauma victims' dreams may reflect an alteration in the process of dream construction or may be related to a protective mechanism which keeps trzlUmatic images from intruding into everyday dreams.
Intense emotions have been documented in several studies of trauma victims' dreams. Feel ings of horror, anxiety, rage, sadness, and frustration are among the most frequently reported. PTSD patients rate their nightma res as being significantly more distressing than do non-PTSD patients. Emotional preoccupations prior to bedtime mav also playa role in the affective content experienced during subsequent sleep. The finding that one's mood prior to sleep is inversely related to positively or negatively experienced dream ~lffect suppmts the idea that dreams may help regulate emotional equilihrium in traumatized individuals.
Some research has been directed at delineating relationships between measures of dream content and specific types of traumas.
Victims of Physical and Sexual Abuse
Themt's of attack, pmsuit, and of one's own death are 1110re frequently found in the dreams recalled bv victims of sexual abuse than in those recalled by control participants. Episodes of verbal and physical abuse are more evident in the dreams of physically abused women when compared to the dreams of controls. Although themes of violence and aggression often characterize women's nightmares, the nightmares reported by victims of sexual abuse are more likely to include unique themes of blood and dismemberment as well as a higher occurrence of male strangers. In addition, the dreams and nightmares of sexually abused women contain more frequent references to negative sexual activity, including themes concerning lack of trust and shame, guilt, jealousy, anger, and violence. These dreams often depict situations wherein elements of sex and aggression are confounded, in which sexuality is unpredictable and often results in fear. Victims of sexual abuse also frequently report the presence of serpents and worms in their dreams as well as references to both sexual and nonsexual body parts.
Victims of War and Violence
Exposure to an environment of war or violence is associated with dreams containing high proportions of aggressive and hostile human interactions. Themes involving immediate dangers to one's life appear more frequently in the dreams of Holocaust survivors, children that have been kidnapped, and children involved in car accidents than in nontrauma populations. It is not unusual for war veterans to report that their traumatic dreams entail being killed in the place of their compatriots. A study of war-exposed Palestinian children found that traumatized children had more dreams with threatening strangers. Their dreams were often composed of attacks, anxiety, persecution, hostility, and nondesirabie endings. In addition, nontraumatized children report more dreams of school and of their peers than do traumatized children.
That said, conflicting results exist regarding the impact of trauma and PTSD on dream content. For example, in addition to having more dreams with threatening strangers, victims of violence also report more dreams referring to their familv, house, affiliations, and human connections than do controls.
Frequency of Dream-Related Disorders
Dream-related disorders, such as posttraumatic dreams, nightmares, bad dreams, and recurrent dreams, are the most frequently reported and most persistent symptoms exhibited trauma victims. Several factors appear to mediate thiS association. First, a positive relationship exists between the degree and of trauma exposure and the frequency of dream·-related disorders. Second, the victim's psychological rc,lction to trauma level of anxiety) positivelv influences the occurrence of nightma res and other dysphoric dream experiences. Third, the time elapsed since trauma exposure appears to play an important role, with reductiolls ill dream-related disorders occurring over time. However, it should be noted that dream disturbances call nevertheless persist for many years following the trauma.
Functional Hypotheses of PTSD-Related Nightmares
Many contemporary dream theorists suggest that dreaming is functionally significant and may subserve a biologically important function, but some argue that dreams are epiphenomenal to neurophysiological activity during REM sleep and have no value in and of themselves. While this overarching question on the function of dreaming is of phenomenological interest, the resolution of this debate is of little clinical relevance for chronic, frequent, and distressing nightmares in PTSD patients. However, understanding the possible role(s) of nightmares as one of the normal initial reactions to trauma exposure, which may also become a perpetuating condition contributing to maladaptive, chronic trauma responsc, has direct clinical implications regarding the development and refinement of effectivc nightmare-specific treatments. The following sections describe the main hypotheses put forth to explain the possible dual role of nightmares occurring posttrauma.
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Nightmares and Emotional Adaptation to Trauma
Several ncuropsychopbysiological hypotheses of the function of dreaming have been adapted to expbin the occurrence of nightmares after exposure to a trauma or other significant life events, and the role of nightmares in the pathogenesis and maintenance of PTSD. Freud proposed that nightmares reflect attempts to master anxiety and guilt associated with a traumatic experience, and to integrate traumatic experiences into one's psyche during sleep. Contemporary hypotheses are based on a similar premise ~ that drcaming serves a function of emotional adaptation to emotionally salient or traumatic events ~ and combine empirical observations supporting the role of REM sleep (and by association, dreaming) in learning, memory consolidation, emotional processing, and adaptatiOll to stress. Given that REM sleep is associated with
Inusclc atonia, and given the lack of detectable logical activation during RENI sleep episodes preceding awakening from nightmares, dreaming and REM sleep may provide a unique psychophvsiological milieu durlllg which traumatic memories can he reexperienced in the absence of physioiogiccli arousal. This process could f,lCilitate the attenuation of emotional and physiological responses associated with these memories, leading to desensitization to the trauma-related memories, including a reduction of nightmares. Prospective dream collection studies in combination with repeated objective assessment of sleep patterns and other physiological parameters of central and peripheral aroLlsal in people at high l·isk for trauma exposure (e.g., disaster workers, police officers, firefighters, deployed military personnel) are necessary to assess the role of nightmares in the recovery of trauma response and PTSD. Stickgold proposed an explicit REM sleep model of the neurobiological substrates potentially subserving emotional processing and integration of traumarelated memories. Specifically, it is suggested that REM sleep provides a unique neurochemical and neurobiological brain state that allows the transfer of hippocampaUy mediated episodic traumatic memories and amygdala-dependent salient affect into cortically distributed semantic networks. It should be noted that tbe possibility has not been evaluated that PTSD-relatecl nightmares may also reflect the failure of compensatory mechanisms aimed at preserving processes such as emotional adaptation, memory consolidation, and sleep continuity.
Sensitization Hypothesis of PTSD Nightmares
While the adaptation process may he successful 11l individuals who recover from trauma exposure, the persistence of nightmares in those who develop PTSD rnay, instead, reflect a failure of dreaming and REM in PTSD sleep to fulfill their role of emotional adaptation and memory integration. In this perspective, nightmares are the outcome of unsuccessful processing during dreaming and REM sleep. In addition, nightmares may directly contribute to the failure of the adaptation and integration process by promoting sensitization (rather than desensitization) to trauma-related memories. PTSD-related nightmares are often associated with awakenings and are accompanied by intense emotional and physiological arousal. Trauma-related nightmare content, sleep disruption induced hy awakfrom a nightmare, ami heightened physiological a nd emotional a rousa I levels that follow such awakenings may contribute to reinforce the occurrence of nightmares and related distress during both wakefulness and sleep. In other words, the I'ecall of nightmares can expose patients to their prior trauma ~1I1d may even induce I'etraumatization, since PTSD nightmares often repeat a traumatic situation in whole or in part, whereas habituation to phvsiologlcal arousal elicited bv these memories does not occur.
There is evidence that frequent and distressing PTSD'related nightmares are associated with increased of daytime reexperiencing, arousal, and avoidlllce PTSD svmptoms. Altern~ltively, some PTSD patients who show clinically significallt improvements in PTSD following exposure-based therapy also report improvements in trauma-related nightmares, suggesting that habituation to trauma memories during wakefulness can also attenuate nightmare frequency, intensi ty, and rei ated distress, Desensitization therapy has also been used successfully for the treatment of trauma-related nightmares. These observations support the hypothesis that chronic nightmares without physiological habituation may indeed contribute to the maintenance of PTSD by sensitizing patients to trauma memones.
Potential Psychophysiological and Neurobiological Underpinnings of PTSD-Related Nightmares
While severa! polysomnographic studies have been conducted in PTSD samples, these sleep measurement methods do not allow the identification of neurobiological underpinnings of trauma-related nightmares or, more of PTSD during sleep. Such an endeavor requires the use of functional sleep neuroimaging approaches. Sleep neuroimaging has not yet been conducted in PTSD patients. However, animal models of the effects of fear conditioning on and neuroimaging sleep studies in humans, have provided valuable insights into the potential neurobiological underpinnings of altered REM and NREM sleep mechanisms following stress exposure PTSD, and into the neurobiology of normal sleep, respectively, While animal models and sleep imaging in healthy persons limit possible extrapolation of neurobiological underpinnings of trauma-related nightmares, findings derived fro111 these two distinct fields provide evidence for functionally significant overlaps between the neurobiology of fear and sleep regulation.
Functional neuroimaging studies conducted during wakefulness in PTSD patients are consistent with animal models of fear conditioning. PTSD is associated with hyperresponsiveness of the amygdab to threatrelated stimuli, and/or a with blunted response of medial prefrontal cortical regions, which exert inhibitory control over the amygdala. Other functional findings include illCl'eased thalamic activity with traullla-related stimuli in PTSD compared to nOIl-PTSD subjects, and hyperresponsiveness of the !loradsvstem. Of note, neuronal activitv in these structures canllot be captured hv conventional sleep measurement methods, which further reinforces the need to tlse sta te-of-thc-science sleep neuroi Illaging methods in patients with PTSD.
[n mdems, cued fear conditioning inCl'C1SCS REM sleep btellcy, decreases RFtvl sleep duratioll ~lI1d numher of RENt bouts, and increases pontogeniculo()cclpital (1'(;0) waves, a marker of alerting mechanisms during sleep and wakefulness analogous to REMs in humans. The effects of fear conditioning on REM sleep in rodents are mediated by amygdalar projections to brain stem regions involved in alerting response and RENt sleep generation. Anatomic:dly, the interconnections that the amygdala shares with the basal forebrain, hypothalamus, preoptic area of the anterior hypothalamus, bra in stem reticular formation, and solitary tract nucleus allow the amygdala to influence both wakefu lness-promoting and sleep-promoting areas. Neuronal fi ring of tbe amygdala varies across the sleep-wake cycle, and stimulation of the amygdala during REM sleep increases PCO waves in REM and NREM sleep, whereas inactivation of the amygdala with tetrodotoxin decreases sleep latency and increases slow-wave activity during wakefulness, REM sleep, and NREM sleep. Conversely, ablation of the amygdala in rhesus monkeys is associated with increased sleep consolidation and total sleep time. These findings indicate that the amygdala is an important modulator of and wakefulness regulation mechanisms.
Sleep neuroimaging studies conducted in healthy persons have reliably shown that REM sleep is a natural activator of the amygdala and anterior paralimbic areas and of the medial pons and thalamus. REM sleep is also associated with relative deactivation of lateral prefrontal parietal regions and primary sensory cortices. These selective activation and deactivation patterns during REM sleep relative to wakefulness have yielded the hypothesis that dreams may reflect the mental representations of high limbic activations ill conjunction with deactivation of high-order cortical regiolls. NREM sleep is a natural deactivator of arousal-promoting structures.
The fUIlCtiollCl Ilv signi ficant interconnections between the amygdala a ncl wakefulness-and sleep-promoting areas, the ullique limbic activation and cortical deactivation p~ltterns observed during sleep In healthy persons, and the functionalneuroanatomic81 findings in PTSD patients durlllg w8kefulness all support a role for a heightened anwgdaLlr activity during sleep ill PTSD, ami prm'lde preliminary guidance for the investigation of the neurobiology of PTSD during REIv1 and "IREM sleep. While the reLltionship between heightened a activity and dream COiltent Clilnot vet he ,lscert;lilled, the role of the amygdala in acquisitioll of the fear response and the emotional s;llience of stimuli r;llStS the possihilitv that heightened ;lIYwgdahr activity durillg RElvl sleep also contrihutes [0 s~lliellt, Ilcg,ltivc ~lSpccts of dreams and nightmares.
Treatments of PTSD-Related Nightmares
Nightlll;ues ~lrc closelv related to sleep disturhances, including inCl'c;lsed sleep btellcv, decreased total sleep time, and incrcclscd Ilumber and duration of awakenings after sleep onset and restless or fitful sleep. Nightmares of tell produce an insomnia-like pattern of sleep disturhance, if not outright inSOlllnla. Sleep ,lVoiciance and fear of da rkness, freq lIent features associated with PTSD-relatcd nightmares, C8n further reinforce the 1118intenance of both nightmares and insomnia.
Recommended (by the Expert Consensus Guideline Series on the treatment of PTSD) first-line treatments include Food and Drug Administr8tion (FDA)-approved SSRls such as sertraline and paroxetine, and cognitive-behavioral interventions such as prolonged exposure and cognitive therapy. However, nightmares are often resistant to such first-line PTSD tre8tments, and adj unctive treatments 8re often required to alleviate PTSD-rehted nightmares.
Several psychological and pharmacological nightmare-focused treatments have been shown to effectively reduce and eliminate nightmares in PTSD patients. Successfully treated nightmare patients often report improvements In sleep quality, feeling more rested upon awakening and having more davtime energy, and reduction in nightmares is a significant predictor of sleep Improvement. In addition, nightmare reduction is associated with marked improvements ill daytime PTSD svmptoms, quality of life, depression 8nd anxiety symptoms, and overall functioning. These findlTlgs suggest that at least in some cases, Dreams and IOnilm"n's in PTSD 659 chronic nightmCl res may represent a pri mary s Jeep disorder rather than a symptom of a psychiatric disorder, and as such can benefit from targeted, adjunctive cognitive-hehavioral or pharmacological treatments.
Imagery Rescripting and Rehearsal
Numerous techniques have been proposed to treat PTSD-related nightmares, including hypnosis, lucid dreaming, eye movement desensitization and reprodesensitization, and inwgery rescripting and rehearsal (lRR). However, only desensitization and IIZR have heen the objects of controlled studies. Only IRR has heen shown to effectively reduce nightmare frequcncv and nightmare-related distress \l1 paticllts suffering from idiopathic, recurrent, or PTSD-I-elatccl nightmares.
IRR for nightmares is composed of two general clements, each of which utilizes several steps in the therapeutic process. The first component is an educational/ cognitive restnlCtli clement, focused on helping IlIghtlll,ut' sufferers to consider their disturhing dreams :IS ;1 le,lI'ncci hch;)vior. The second component is ,111 ccillcatiollitr;lilling clemcnt, which teaches nightmare patients ,1hout the nature of human illlagerv and how to Ill1plement a specific set of imagery steps to decrease n Gener,lllv, patients are shown how a llIghtnure can be effectively treated as a problem in and of itself, without any discussion or emphasis on prior traumatic events or nonslcep-related PTSD SVl11ptOl11s. 1\S such, IRR seeks to minimize the use of exposure therapy as an ingredient in its procedures.
When learning IRR, patients are instructed to modifv an origin81 nightmare in any manner of their preference, and to create a new dream scenario. The new dream scenario is then rehearsed in session, and practiced each day until the next session. The rationale is that the rescripting and rehearsal of new dream imagery during the day can replace or alter nightmare scenarios experienced during sleep. Generally, patients report reductions in nightmare frequency and intensity within 6-12 weeks, and improvements are maintained for as long as 30 months.
Several variations of IF,-P,-have no\v been described.
The distinguishing features between variations of IRR revolve mound the degree of exposure used during treatment sessions and/or the specific applicatioll of the technique during the sessions. 1RR can be delivered in group or individual formats. htrn",·p.: in PTSD ingredient in this treatment. The observed increase in mastery IS all the more remarkable given that IRR does not include instructions to increase mastery when the technique is descri bed during treatment. Although these data are consistent with the view that a dysfunctional imagerv system is involved ill traumatic nightmares, more work is required to elucidate the reLltionship between variables related to patient characteristics traumatized vs. nontrallmati zed, presence of psych i;ltric and sleep disorders, dispositional factors, degree of distress), nightmare content and type replicative, recurrent, lifelong, idiopathic), and therapeutic effects (e.g., enhanced perceived control, modes of emotion expressi on and representa ti on).
Prazosin
PraZ()Sill is ~1 celltral Y. i adrenoreceptOl" blucker that is FDr\-;lpproved for the treatmcnt of hypertension. Prazosin is currently the most efficacious treatment for PTSD-related Illghtl11ares in military veterans and clvili a 11 popula tiolls wi th PTSD. Promising resul ts for the use of praz()sin to reduce PTSD-related nightmares became avaibblc after the Expert Consensus Guideline Series on the treatment of PTSD were estZlblished. Results from controlled trials llldicate that prawsin effectively reduces chronic PTSD-related nightmares in military and civilian sample groups with PTSD. Reduction in nightmares with prazosin is associated with clinically meaningful improvements in sleep quality, overall PTSD and daytime functioning 111 CO\11-bat veterans with chronic PTSD. Most patients experience a recurrence of insomnia and nightmares upon prazosin discontinuation. The drug is well tolerated by patients, is associ8ted with minimal side effects, and no adverse events have been reported with long-term use.
Serotonin-Potentiating Drugs
Randomized controlled trials on the efficacy of FDA-approved SSRls for the treatment of PTSD (i.e., sertraline and paroxetine) either did not measure improvements in sleep using validated measures, or reported minimal improvements in nightmares or overall sleep quality. In fact, some SSRls may increase the numbC\" of arousals during sleep and decrease total sleep time. Open-label trials with fluvoxaminc suggest moderate improvements in PTSD-related nightmares, but randomized controlled trials have not been conducted and side effects may impede tolerability. Open-label trials and case reports suggest that serotonin-potentiating l1ol1-SSRls, sllch as nefazodone and trazodone, can be associated with reductions in PTSD-related nightmares and sleep disruption. However, double-blind randomized controlled trials in PTSD samples are not available. The need for rigorous randomized controlled trials is highlighted by the example of cyproheptadine. Initial case series suggested that cyproheptadine was a potent agent for the alleviation of PTSD-related nightmares. However, a subsequent double-blind, randomized controlled trial in Vietnam veterans with 1'TSD found that cyproheptadine could in fact exacerbate nightmares and sleep disrtlption. A few randomized controlled trials have evaluated the of monoamine oxicbse inhibitors and tricyclic antidepressants for PTSD, and slight to moderate improvements were reported in some, hut not all, studies. Optimal doses, durability of therapeutic gains, side effect profiles, and tolerabilitv have not been assessed specificallv for PTSD-related nightmares ~lnd sleep disruption with non-SSRls, mOl1oamine oxidase inhibitors, or tricyclic antidepressants. It should he noted that very few trials t,l rgeting cl inica II y meani ngful reductions in PTS Drelated nightmares and sleep disturbances have used specific nightmare measures (e.g., questionnaires, sleep or dre~lm jogs) as primar\" outcome measures. Such measures are necessarv to determine the effects of targeted treatments on specific aspects of nightmares, such as frequency, intensity, nightmare-induced sleep disruption, and ;lssociated distress.
Other Pharmacological Agents
Several medications that have sedative properties have been used in PTSD patients. Antipsychotics such as olanzapine and quetiapine have been tested in 1'TSD and have been associated with mixed findings as to their potential for reducing PTSD-related nightmares and insomnia. Despite the lack of evidence for their efficacy in reducing both dayti me and nighttime PTSD symptoms, benzodiazepines are often prescribed to patients with PTSD. An open trial with zolpidem, a nonbenzodiazepine hypnotic, reported ill1prOVetnents ill sleep and some improvements in nightmares in military veterans with PTSD. Case series reports on other pharmacological agents, such as topiramate, respiridone, and gabapentin, among others, are also available. While most cases report some degree of improvement in nightmares and insomnia in PTSD patients, proper randomized controlled trials are necessary to fully assess the efficacy of these agents as adjunctive PTSD treatments for nightmares and insomnia, and to determine associated health risks in light of side effects sLlch as tolerance, weight gain, and glucose dysregulation. This article presents the definition of nightmares and diagnostic features, followed by a discussion on the prevalence and frequency of nightmares and related methodological issues. The potential etiologic factors of nightmares, associated features, and available pharmacologic and cognitive-behavioral treatment strategies are reviewed. Current diagnostic classifications define nightmares as frightening dreams that awaken the sleeper. However, fear is not the only emotion reported in nightmares; and the importance of the awakening criterion for functional and sleep impairments associated with nightmares has been debated in the literature. These points are briefly summarized here. In this article, the term nightmare is broadly used to refer to disturbed dreaming that mayor may not be accompanied by an awakening, and that is associated with clinically meaningful levels of daytime distress, functional impairments, or sleep disruption.
In reviewing available data on nightmare prevalence and frequency estimates, the need for more unified methodological approaches and longitudinal designs in future studies is highlighted. Although the literature is limited on the etiology of nightmares that occur outside the context of stress or traumatic responses, this article presents hypotheses previously suggested on the correlates and potential underlying mechanisms of nightmares. Selected associated features of nightmares (ie, psychopathology and sleep disturbances) are presented, and available and promising treatment strategies are described. Some pharmacologic and cognitive-behavioral treatments of nightmares have been shown to effectively reduce and eliminate nightmares, but few rigorous, randomized controlled clinical tria!s have been conducted. Finally, future directions for methodological consideration, research investigations, and clinical practice are offered.
DEFINITION
The Diagnostic and Statistical Manual of Mental Disorders, fourth edition, text revision (DSM-IV-TR) 1 and the International Classification of Sleep Disorders, second edition (ICSD-II)2 converge on defining nightmares as "intensely disturbing dreams that awaken the dreamer to a fully conscious state and generally occur in the latter half of the sleep period." However, these diagnostic classifications also differ on 2 key points. Firstly, they differ on whether nightmare-associated emotions are limited to fear and anxiety (DSM-IV-TR) or can include all dysphoric emotions, such as anger or despair (ICSD-II). Secondly, only the DSM-IV-TR specifies a criterion that the nightmare or resulting sleep disturbance is associated with significant distress or impairment in waking functioning. The awakening criterion has stimulated significant controversy in the field. Historically, distressing dreams that do not lead to an immediate awakening (at least one that is remembered by the dreamer) have been labeled as bad dreams
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Theorists have suggested that dreaming serves an extinction function, and that the awakenings associated with nightmares, but not bad dreams, disrupts this extinction process 46 Consequently, many studies dichotomize nightmares and bad dreams as distinct phenomena. However, evidence concerning the importance of awakening to associated distress or psychopathology remains mixed and raises questions about the clinical usefulness of this distinction. Specifically, available treatments to reduce unpleasant dreams usually focus on the extinction of distressing content, rather than on the extinction of these associated awakenings.
Some have argued that all dysphoric dreams fall on a continuum; in this view, nightmares are more intense than bad dreams, both being versions of the same basic phenomenon. Others support the view that the distinction between nightmares and bad dreams relates to underlying differences in the intensity of the emotional content.? However, findings from studies that have investigated differences in dream content intensity between nightmares and bad dreams show small differences between the 2 phenomena. For example, Blagrove and Haywood 8 reported that dreams judged to have caused awakenings were rated as more unpleasant (in line with nightmares as more intense versions of bad dreams). However, the statistically significant differences in emotion intensity ratings were less than 0.3 on a 7 -point scale. A similarly small difference (approximately 0.7 on a 9-point scale) in ratings of emotional intensity in nightmares compared with bad dreams was also reported by Zadra and colleagues 9 These small differences in dream intensity between nightmares and bad dreams suggest that dream intensity may not be the primary mechanism that distinguishes nightmares from bad dreams. The reliability of patients' nocturnal awakening memories is another important, though minimally considered, aspect of the awakening criterion's clinical significance in defining nightmares. It is possible that bad dreams lead to much shorter awakenings, leading to amnesia of the arousal.
For instance, awakenings less than 3 minutes in duration are often associated with retrograde and anterograde amnesia w Blagrove and Haywood 8 attempted to address this concern by assessing the dreamers' subjective certainty about whether their disturbing dreams woke them up, and they found that participants were generally confident making this decision and particularly so when dreams were very unpleasant. Nevertheless, the lack of objective measures to accurately evaluate the duration of these awakenings makes it difficult to ascertain that bad dreams associated with an awakening are less subject to memory biases.
As indicated earlier, there is divergence between the diagnostic classifications of nightmare distress. Some have argued that nightmare-related distress is more clinically relevant than nightmare frequency to daytime functioning and psychopathology.'! From this perspective, nightmares are viewed as a manifestation of the cross-state continuity of distress from waking to sleeping. In support of this assertion, distress is only weakly related to nightmare frequency, 11 but it may be more robustly associated with sleep disturbance 12 and measures of psychopathology13,14 than with frequency. However, assessments of nightmare distress are vastly underrepresented in the Iiterature,4 being limited to 1 validated scale, the Nightmare Distress Scale,11 which may potentially confound nightmare distress with nightmare frequency.15 Again, longitudinal studies with reliable frequency and distress measures are necessary to fully evaluate the clinical significance of nightmare distress.
Neither classification system includes a criterion for the duration of the nightmare problem, perhaps because the cause of distressing nightmares is often undetermined, or because the clinical meaningfulness of duration of the nightmare problem has not yet been assessed empirically.
Nightmares should not be confused with other distressing nocturnal phenomena. Nightmares are most readily distinguished from other similarly distressing nocturnal events by the extent of mental content, the confusion or disorientation upon awakening, and the presence or absence of memory of the event on the following morning. Sleep recordings show that these distressing nocturnal episodes generally occur in different sleep stages. The particular treatments that are effective for each category of event also vary.
Sleep terrors are associated with intense autonomic aroLisal. They can begin with a piercing scream, but they are paradoxically associated with difficulty in awakening the sleeper from the episode and in the sleeper returning to deep sleep after the episode.
2 In contrast, there is little confusion or disorientation upon awakening from nightmares, and episodes are vividly recalled the following morning. For sleep terrors, if the sleeper has any recall of the event, recollections the next morning are, at best, vague or fragmented descriptions of frightening images. 16 Although nightmares primarily originate in rapid eye movement (REM) sleep, sleep terrors occur in non-REM sleep, specifically the slow-wave sleep of stages 3 and 4.
In contrast to nightmares and sleep terrors, nocturnal panic attacks often occur in the first few hours of the night during the transition from light (stage 2) sleep to deep (stage 3) sleep.
Intense arousal is inherent in nocturnal panic attacks, leading to abrupt and complete awakening from sleep in a state of panic, without an obvious trigger and usually without screaming; the panic attacks are associated with a difficulty in returning to sleep.17 Complicating differential diagnosis is the co-occurrence that has been documented between these parasomnias, such as' an association between monthly nightmares and an increased incidence of night terrors. 19 Although sleep terrors and nocturnal panic attacks share a common predisposing condition -sleep deprivation leads to an increased incidence of both 17, 18 -the existing evidence suggests that nightmares lead to sleep disturbance rather than the reverse (see later discussion on association with sleep disturbance).
PREVALENCE AND FREQUENCY
Nightmares are most prevalent during childhood and young adulthood and decline thereafter.4 However, prevalence estimates in the general population in all age ranges vary and overlap substantially. From childhood through to early adolescence, between 5% and 50% of children have nightmares, with the prevalence of nightmare "problems" generally falling into the 20% to 40% range. In comparison, up to 85% of adults report at least 1 nightmare within the previous year, 8% to 29% report monthly nightmares, and 2% to 6% report weekly nightmares. 19 " 21 The estimates of weekly prevalence of nightmares have proved consistent across cultures.
12 , [20] [21] [22] Similarly robust are findings of a lower prevalence of nightmares among the elderly, who report at levels 20% to 50% of that of young adults. 23 -25 The variability in estimates is due, in part, to differences in the criteria used, the definition of nightmares, the time frame of assessments, the emphasis on distress or nightmares as a "problem" across studies, and the type of informants (eg, patients, primary care physicians, parents). In studies of children, the information, generally gathered from mothers, may show underestimation in the prevalence of nightmares and may be confounded by the occurrence of other common childhood parasomnias, such as sleep terrors. Nightmare prevalence estimates are derived nearly entirely from cross-sectional data.
Sex differences in nightmare prevalence are one of the most consistent findings in the literature,26 with a higher percentage of women reporting nightmares; unacknowledged exceptions do exist. 27 Researchers have offered various explanations that are not mutually exclusive for this difference: (1) self-report biases in women, (2) greater vulnerability to risk factors including abuse in women, (3) anxiety and mood disorders in women, (4) sex differences in coping styles, and (5) biologic differences in emotion processing4, 11,28 .. 30 Together, these findings highlight the need for conducting longitudinal studies using established diagnostic definitions, an important future step to establishing prevalence rates over the life span. Longitudinal studies would also provide new information on the potential modulators (eg, sex, coping styles, biologic factors) that may contribute to enhanced vulnerability or resilience to chronic nightmares. Although the developmental trajectory remains to be clarified, all estimates to date indicate that nightmares are a prevalent problem, underscoring the need for appropriate clinical identification, assessment, and treatment.
Oata concerning the frequency of nightmares are also characterized by substantial variability, mostly because of differences in the assessment methods used across studies. Common methods to assess nightmare frequency are prospective nightmare logs or retrospective estimates of the number of nightmares that occurred over a predetermined period of time (usually 1 month to 1 year). Oaily dream/nightmare logs that are completed on awakening in the morning can be a simple checklist or a more extensive dream diary used to record nightmare narratives.
Numerous studies have assessed nightmare frequency, using retrospective or prospective measures. The differences between retrospective and prospective methods affect frequency estimates. Specifically, retrospective estimates have yielded frequency estimates ranging from less than once per year to once per month,27 whereas prospective measures have consistently provided higher nightmare frequency estimates, particularly when compared with 1-year retrospective nightmare frequency measures 27 Studies that have compared both assessment methods have reported that retrospective questionnaires underestimate nightmare frequency by a factor of 2.5 to 10 T .
13 , 31 Many of these studies have been conducted with undergraduates who are in their first semester of college, a time of social and emotional upheaval for many. The latter method may provide overestimates of nightmare frequency in noncollege populations. Differences in frequency estimates that are derived from retrospective and prospective measures are generally interpreted as indicating that retrospective measures underestimate nightmare prevalence, Monitoring of nightmares could potentially increase or decrease their frequency. Nevertheless, prospective nightmare measures have been recommended as the gold standard. 4 , 27 The most sophisticated study on the topic evaluated the comparability of frequency estimates for nightmares and bad dreams, when assessed by 1-year and 1-month retrospective measures and by narrative and checklist prospective measures. 28 Including both types of prospective measures was intended to address the question of whether intensive monitoring (with narrative logs) results in higher frequencies than a less demanding approach (using checklist logs). In contrast to predictions, narrative logs produced lower nightmare frequency estimates than checklist logs that did not significantly differ from the 1-month retrospective measure and were possibly higher than the 1-year retrospective measure, When examining bad dreams, both prospective measures produced higher estimates than the retrospective measures, but the prospective and retrospective estimates for bad dreams were not significantly different from one another.
Attempts to assess nightmares via polysomnographic (PSG) recordings in the laboratory have been difficult, because nightmares tend to occur less frequently under these conditions. 32 Even posttraumatic nightmares (see the etiology section) have a low incidence (1 %-10% vs up to 85% of nights) in the sleep laboratory relative to naturalistic conditions 33 ,34 A pilot study, using ambulatory PSG recording, suggested that the presence of the PSG, rather than the setting, is the crucial factor in the lower observed frequency. In a sample of 12 inpatients in a psychiatric clinic, Spoormaker and colleagues (unpublished data, 2004) found a significantly lower nightmare incidence (8% vs 34.5%) using ambulatory PSG over two 24-hour recordings compared with daily logs over 7 days, However, the generalizability of this study outside of inpatient settings is uncertain, and PSG studies of nightmares remain too few to draw firm conclusions.
ETIOLOGY
Nightmares are associated with a range of psychiatric symptoms, full-blown psychiatric disorders such as posttraumatic stress disorder (PTSD), and sleep disturbances. Although some psychiatric, personality, sleep, and biologic correlates of nightmares have been described, most extant studies are cross-sectional, precluding conclusive determination of causality and etiology. Although longitudinal studies are awaited, findings suggest that traumatic events, waking psychological distress, or sleep disturbance may contribute to the onset and maintenance of nightmares. Some theories that have been offered on the etiology of nightmares are briefly summarized in the following sections.
Idiopathic Versus Posttraumatic Nightmares
An important etiologic distinction made to date is the difference between idiopathic and posttraumatic nightmares. Idiopathic nightmares refer to nightmares with unknown cause that are unrelated to a specific traumatic event or PTSD. Posttraumatic nightmares refer to dreaming disturbances that are part of the stress reaction following exposure to a traumatic event, either during the acute stress response or over the course of PTSD, Nightmares are a core feature of PTSD, with up to 90% of individuals with PTSD reporting disturbing dreams with some degree of resemblance to the actual traumatic event. Nightmares may occur as frequently as 6 nights a week in individuals with PTSD,35 and they may continue for up to 40 to 50 years after the original trauma,36,37
The distinction between idiopathic and posttraumatic nightmares has not been firmly established in most of the literature available to date, Given the emerging evidence that persistent nightmares in the wake of a traumatic incident predict later posttraumatic symptoms,38 making a differential diagnosis may be particularly important for early intervention to ward off PTSD. In addition, these 2 types of nightmares may differ in their associated sleep disturbance (see the following section on associated features) and in the timing of their occurrence during the sleep period. Further research is necessary to characterize fully the etiology, phenomenology, trajectory, and functional consequences of these ostensibly different categories of nightmares.
Nightmares Due to Thin Psychological
Boundaries?
Hartmann and colleagues 39 ,4o proposed the constructs of "thin" and "thick" psychological boundaries to characterize chronic (idiopathic) nightmare sufferers versus those with little or no nightmare experience. Frequent nightmare sufferers tend to be more emotionally sensitive, open, and reactive to elements of their internal and external environments. Individuals with no nightmares, on the other hand, tend to be less reactive to internal and external influences. Several subsequent studies have reported positive findings on the relationship between clinical features of schizophrenia-spectrum disorders and nightmare frequency41,42
Disturbance in a Generally Adaptive Process?
A prevailing assumption is that dreaming is adaptive,43 and thus nightmares may constitute an anomaly in the adaptive process, also described as "a failed dream. ,,43 However, the evidence in support of this hypothesis is scant. Flanagan 44 suggested that sleeping, not dreaming per se, is an adaptive process. In contrast, it has also been suggested that nightmares themselves might be the adaptive process. For example, Picchioni and colleagues 45 reported that nightmares are positively associated with waking attempts to cope with stress, suggesting that nightmares may serve a beneficial function. However, the absence of a direct assessment of successful outcomes of coping in this study makes it difficult, at best, to relate nightmares to functional outcomes. The potential specific role of nightmares in adapting to waking stressors and the specific conditions and mechanisms that contribute to successful or unsuccessful adaptation to stress through dreaming disturbances remain to be investigated.
Genetic Predisposition to Nightmares?
A single study has investigated the possible genetic contributions to nightmares. Using data from the Finnish Twin Cohort study, a nationwide questionnaire study that included 1298 monozygotic and 2419 dizygotic twins aged 33 to 60 years, Hublin and colleagues 46 found a genetic influence on nightmares that differed slightly between childhood and adult nightmares. Genetic effects accounted for an estimated 45% of the phenotypic variance in childhood and for an estimated 37% in adulthood. The odds ratios for associated psychiatric disorders also varied by age group; children most frequently experiencing nightmares were 3.67 times more likely to have a psychiatric disorder than those who never experienced nightmares, whereas adults with frequent nightmares had an odds ratio of 5.87. This suggests that nightmares during adulthood have a strong association with psychopathology. Again, these findings highlight the need for longitudinal studies to rigorously assess the moderators and predictors of the trajectory of nightmares and their clinical outcomes over time.
ASSOCIATED FEATURES
Nightmares are associated with sleep disturbance, but longitudinal studies are required to ascertain the directionality of this association. Sleep disruption as a consequence of nightmares is implicit in their definition, given the criterion of awakening to a fully conscious state. Empirical data bear this out, because frequent nightmares are associated with increased reports of sleeponset and sleep-maintenance insomnia, more frequent nocturnal awakenings, and worse sleep quality.21,26,47 Breathing problems (eg, asthma) and snoring are linked to idiopathic nightmares,48 whereas an association with full-blown sleep apnea has been reported in posttraumatic nightmares 49 Although longitudinal data are limited, 1 prospective study found that posttraumatic nightmares occurring 3 months after a motor vehicle accident were associated with current sleep-onset and sleep-maintenance problems and predicted sleep maintenance difficulties after 1 year. 50
Objective indices of sleep disruption, as measured by PSG, suggest that idiopathic and posttraumatic nightmares have been associated with different effects on sleep. Although both nightmare types share an association with elevated numbers of periodic limb movements, posttraumatic nightmares are related to longer and more frequent awakenings 51 this relationship is a possible consequence of a lowered arousal threshold during sleep in PTSD,52 although the evidence on this is mixed 53 In addition, posttraumatic nightmares may occur earlier in the night than idiopathic nightmares,54 but this was not replicated in a recent study 51 Individuals with idiopathic and posttraumatic nightmares also did not differ on total sleeping time, sleep onset latency, slow-wave sleep, number of microarousals, or any of several REM-related parameters 51
Waking Disturbance and Psychopathology
Perhaps most relevant to clinical discussions of nightmares is their relationship to waking disturbance or psychopathology. In general, nightmares appear to be linked to a greater incidence of mental complaints in healthy and clinical populations.
An important part of the nightmare literature has focused on the relationships between personality traits and nightmare frequency. The association between nightmares and anxiety has been most widely investigated. Modest associations between different measures of trait and state anxiety (eg, death anxiety scales, ego strength scales, manifest anxiety scales, and nightmare frequency assessed retrospectively) have been reportedl.3155-6o However, the association between nightmare frequency and anxiety is weakened when assessed with daily nightmare logs instead of retrospective questionnaires.
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Nightmare-related distress, rather than nightmare frequency, seems to be more strongly related to anxiety.13,1431 In general, studies have consistently reported mild-to-moderate correlations between nightmare frequency and distress and general symptoms of anxiety, mood, somatization, and hostilityl13
As mentioned previously, nightmares are a core feature of PTSD and may be implicated in the pathophysiology of the disorder. In addition, a pretrauma history of nightmares (possibly idiopathic nightmares) predicts the severity of PTSD c1 PTSD-related nightmares are often resistant to first-line PTSD treatments, but they respond well to pharmacologic and cognitivebehavioral treatments (see the following section).
Nightmares have also been linked to suicidality. Cross-sectional studies have demonstrated an association between nightmares and both suicidal ideation 6263 and actual suicide attempts 63 ; nightmares were the only sleep variable associated with suicidality in a sample of suicide attempters, after controlling for Axis I disorders (including PTSD) and symptom intensity,s4 One prospective study found that nightmare frequency, per 1 month retrospective self-reports, was related to the risk of suicide, with a 57% higher risk among those reporting occasional nightmares and a 105% higher risk among those reporting frequent nightmares 65 Although all of these studies were statistically controlled for possible confounding factors such as sex, depression, and insomnia, only 1 study was controlled for PTSD. 65 This is an important limitation because PTSD is also linked to suicidality.66
TREATMENTS
Most available pharmacologic and psychological literature on the treatments of nightmares is derived from case reports and clinical trials targeting nightmares occurring in the context of PTSD
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Although very few studies have evaluated the effects of these treatments on nightmares of unspecified causes, there is little evidence suggesting that different outcomes would be observed.
Pharmacologic Treatments of Nightmares
By far, the most common treatments of nightmares involve pharmacotherapy. There have been numerous open-label trials, with various agents for the treatment of nightmares. To date, the most effective of available treatments of PTSD-related nightmares is prazosin. Prazosin is an alpha1-noradrenergic antagonist, which is used nightly and associated with clinically meaningful improvements in nightmares, accompanied by reductions in other sleep disturbances and daytime PTSD symptoms. Placebo-controlled studies of prazosin have consistently reported positive effects on nightmares in military and civilian samples 6s - 73 However, nightmares recur with prazosin discontinuation. Several other pharmacologic approaches have also been used with mixed results. Tricyclic antidepressants and monoamine oxidase inhibitors were among the first agents tested for nightmares because of the suppressant effects on REM sleep, but side effects and contraindications limit their clinical use. Selective serotonin reuptake inhibitors (SSRls), such as paroxetine, sertraline, and fluoxetine, are Food and Drug Administration (FDA)-approved as first-line recommended PTSD treatments, but their efficacy for nightmares is inconsistent across clinical trials. Trazodone and nefazodone, 2 serotonin-potentiating non-SSRI agents, have been associated with moderate-tolarge beneficial effects on nightmares in openlabel and controlled trials l4 -
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Cyproheptadine, an antihistamine with serotonin receptor antagonist properties, has not been found effective for reducing PTSD-related nightmares in a randomized controlled stud yl8,79 Similarly, guanfacine, an alpha2-adrenergic receptor agonist, was not found to be effective in reducing nightmares in patients with PTSD in 2 randomized controlled trials ao . 81 Benzodiazepines are often prescribed to patients with PTSD, possibly as agents to manage sleep disturbances,82 .. 84 despite lack of evidence as to their effectiveness. Two randomized controlled trials found no support for the efficacy of benzodiazepines as treatment for nightmares in PTSD a5 . 86 Although benzodiazepines can reduce nightmares associated with REM sleep behavior disorder,S? their efficacy in alleviating nightmares from other causes is unknown. 
Cognitive-behavioral Treatments of Nightmares
Cognitive-behavioral treatments of nightmares have focused on 2 general approaches. The first approach is derived from the literature and treatment methods for anxiety disorders. Specifically, desensitization is implemented with the use of repeated exposure to the fearful nightmare content and with habituation to the emotional response triggered by nightmare imagery. Three controlled studies 94 - 96 have assessed the efficacy of desensitization in reducing nightmare frequency, nightmare intensity, psychological symptoms (eg, anxiety, fear, depression, hostility, and general psychological distress), and sleep complaints. Although desensitization studies did not specify the cause of nightmares in patients enrolled in these trials, all have consistently reported improvements in nightmares and also in sleep disturbances and daytime symptoms of anxiety 96 Desensitization studies that used nightmare recording or relaxation 94 as control treatment conditions also noted posttreatment improvements in nightmares. Improvements in nightmares were also found over the periods of follow-up assessments for patients randomized to the desensitization groups, which ranged from 1 to 7 months after treatment. Together, these studies suggest that desensitization can be an effective treatment for nightmares. The efficacy of desensitization for PTSD nightmares, however, has not yet been evaluated.
The second behavioral approach for the treatment of nightmares is imagery rehearsal therapy (IRT) and its variants. The goal of IRT is to decrease the frequency or intensity of nightmares by (1) A variant of IRT, called Exposure, Relaxation, and Rescripting Therapy (ERRT10o), has also been associated with long-term improvements in nightmare frequency, depression-symptom severity, PTSD-symptom severity, and sleep quality for trauma-related nightmares, compared with effects observed in a wait-list control group. ERRT is a combination of (1) education about trauma, PTSD, and sleep; (2) exposure to the nightmare content and distressing themes; (3) diaphragmatic breathing and daily progressive muscle relaxation; and (4) rescripting of the nightmare scenario guided by the therapists and other members of the treatment group. Contrary to IRT, ERRT encourages exposure to the distressing nightmare content. Future research is awaited to determine which patients to treat and how much exposure should be given in the treatment of nightmares.
To date, IRT has shown efficacy with PTSD and non-PTSD related nightmares 97 ,98,101,102 in civilian and military samples 99 ,103 However, to fully evaluate and compare the efficacy of different cognitive-behavioral techniques for the treatment of nightmares, more stringent control treatment conditions and direct comparisons between IRT approaches and desensitization or exposure are required.
Other psychological approaches have also been used in the treatment of nightmares. For instance, positive case reports and case series are available in the literature for lucid dreaming,104 hypnosis,105 eye movement desensitization and reprocessing,106 and psychodynamic therapy.1 07,108 These approaches await controlled clinical trials to determine efficacy for nightmares and the related impact of sleep disturbances and daytime functional impairments and distress.
SUMMARY
Nightmares, a common experience for most of the general population, are even more prevalent and frequent among clinical populations. This increased prevalence is consistent with converging evidence of their potential clinical significance across diagnostic categories. Accumulating evidence links nightmares to waking distress and psychopathology; prospective studies suggest that nightmares may be a risk factor for PTSD and increased suicidality, offering new venues for prevention and interventions.
Methodological limitations and differences, across studies to date, preclude a more complete understanding of many aspects of this fascinating phenomenon. Thus, more rigorous methods are needed to address numerous areas. Firstly, the variability in assessment methods may have led to imprecise prevalence estimates, and this limits our ability to compare findings across studies. Studies of nightmares under controlled laboratory conditions may provide novel insights into the psychophysiological correlates of these nocturnal events; however, multi-night designs, with larger samples studied under ecologically valid conditions, are required to accurately evaluate the frequency and prevalence of nightmares in the general population and in clinical samples. Such studies would also permit assessments of the relationships between nightmare distress and frequency. Secondly, many questions remain regarding the cause and outcomes of nightmares. Most findings concerning nightmares and waking function are limited to correlations based on cross-sectional observational data. Experimental and longitudinal designs are required to address questions around the relationships between nightmares, sleep disturbance, and psychopathology. Even in the case of posttraumatic nightmares, where a clear event precedes the onset of nightmares, little is known about the biopsychosocial pathways through which the trauma exposure affects dreaming. More randomized controlled studies are necessary (1) to evaluate and compare available and promising treatment strategies and (2) to establish guidelines and algorithms to guide clinicians in the treatment of nightmares. Effective nightmare treatments can be used as probes to test specific hypotheses regarding the psychophysiological mechanisms underlying nightmares.
A small contingent of highly dedicated scientists is responsible for the laudable advancements in the nightmare literature to date. These researchers have also posited some compelling hypotheses that deserve more rigorous testing. Opportunities for novel contributions to and advancement of this important area of clinical investigation await the efforts of the broader research community. 
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Sleep disturbances are a core feature of p(}sttr~mlll~ltic stress disorder (FTSD). FTSI) is characterized by three symptom clusters that arise and persist for more th~lIl olle l1lonth after eXjlosure to , 1 tr,lum~lti<: event, defined as experiencing or witnessing of a real or perceived threat of death or illinrv to one's self or others, and associ ated with inll'llsc of ft';!!", horror, hYf)erarousal.
The symptom clusters ~lrc symptoms, ~lvoidance and and insollllli~! arc hallmarks of PTSD (Ross el a!., ILJ8LJ) Nightmares rcCer to replays of traumatic events, but other unpleasant cireams are also common and associ,lted with comparable distress. Insomnia refers to difficulty falling or staying asleep. Other sleep disturbances endorsed by patients with PTSD include bad dreams unrelated to traumatic events, simple and complex motor behaviors, nocturnal panic attacks, and sleep terror, (Germain et a!., 20(5). Although considned symptoms of stress reactions, sleep disturbances can develop into persistent and independent comorbid conditions, which are often resistant to pharmacological or cognitive-behavioral PTSD treatments.
Findings from animal and human studies support the hypothesis that sleep disturbances play an important role in the development and persistence of PTSJ) and associated poor health outcomes (Cermain et a!., 2()08). For instance, the occurrence of sleep disturbance after exposure to traumatic events increases the risk fur developing chronic PTSD, and sleep disturbances independently contribute to poor clinical outcomes in patients with PTSD. Additionally, clinical observations suggest that the norm~dizati(ln of sleep dis turbances ll1~ly be criticd in rcmission and recovery. Sleep-focused treatments, such as imagery rehearsal for nightmares and pr,l-/(lsi n (a noradrcnergic al pha -J an tagonist), sleep and PTSD in combat-exposed military veterans, Our studies include a broad array of sleep assessments including validated self report measures, objective measures of sleep and wakefulness patterns, such as actigra·· phI' (a wristwatch-like device composed of accelerometers to monitor and record activity/movement levels across several 24-hour periods), and in-home or laboratory-based sleep studies (polysoll1nography), quantitative electroencephalography (q EEG), and positron emission tomography. Understanding the psychophysiological and neurobiological underpinnings of PTSD across the sleep-wake is essential in developing and refining prevention and intervention strategies to enhance resilience to traumatic stress and to hasten the recov, cry of patients with PTSD.
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